Do regional differences in adipocyte biology provide new pathophysiological insights?

被引:216
作者
Lafontan, M [1 ]
Berlan, M [1 ]
机构
[1] Univ Toulouse 3, Unite Rech, Obesites Unite, INSERM 586,Inst Louis Bugnard,CHU Rangueil, F-31403 Toulouse 4, France
关键词
D O I
10.1016/S0165-6147(03)00132-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obesity is an increasing health problem in many countries. Striking differences exist in the magnitude of the impact of different obesities on comorbidities. Individuals with peripheral obesity ('pears') possess fat distributed subcutaneously in gluteofemoral areas and the lower part of the abdomen, and are at little risk of metabolic complications. Conversely, individuals with upper-body obesity ('apples') accumulate fat in subcutaneous and visceral deposits and are more prone to metabolic and cardiovascular problems, particularly when visceral fat deposits are abundant. In this article, whether the different risk factors for obesity of 'apples' and 'pears' are largely related to the heterogeneity of function and responsiveness of the adipocytes from visceral and subcutaneous deposits is questioned. Possible pharmacological approaches to the treatment of obesity and related diseases are also considered.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 87 条
[1]   Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].
Adams, M ;
Montague, CT ;
Prins, JB ;
Holder, JC ;
Smith, SA ;
Sanders, L ;
Digby, JE ;
Sewter, CP ;
Lazar, MA ;
Chatterjee, VKK ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153
[2]   Catecholamine-induced lipolysis in obesity [J].
Arner P. .
International Journal of Obesity, 1999, 23 (Suppl 1) :10-13
[3]   BETA-ADRENOCEPTOR EXPRESSION IN HUMAN FAT-CELLS FROM DIFFERENT REGIONS [J].
ARNER, P ;
HELLSTROM, L ;
WAHRENBERG, H ;
BRONNEGARD, M .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (05) :1595-1600
[4]   Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat - Evidence of differences between visceral and subcutaneous deposits [J].
Bastelica, D ;
Morange, P ;
Berthet, B ;
Borghi, H ;
Lacroix, O ;
Grino, M ;
Juhan-Vague, I ;
Alessi, MC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (01) :173-178
[5]   Systemic and regional free fatty acid metabolism in type 2 diabetes [J].
Basu, A ;
Basu, R ;
Shah, P ;
Vella, A ;
Rizza, RA ;
Jensen, MD .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 280 (06) :E1000-E1006
[6]   Free fatty acids and pathogenesis of type 2 diabetes mellitus [J].
Bergman, RN ;
Ader, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (09) :351-356
[7]   Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? [J].
Bergman, RN .
DIABETOLOGIA, 2000, 43 (07) :946-+
[8]   PHARMACOLOGICAL PROSPECTS FOR ALPHA-2-ADRENOCEPTOR ANTAGONIST THERAPY [J].
BERLAN, M ;
MONTASTRUC, JL ;
LAFONTAN, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (07) :277-282
[9]   PORTAL ADIPOSE-TISSUE AS A GENERATOR OF RISK-FACTORS FOR CARDIOVASCULAR-DISEASE AND DIABETES [J].
BJORNTORP, P .
ARTERIOSCLEROSIS, 1990, 10 (04) :493-496
[10]   Interaction between free fatty acids and glucose metabolism [J].
Boden, G .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2002, 5 (05) :545-549